Liver cancer drug trial halted: could cadonilimab stop recurrence?
NCT ID NCT06851104
First seen Feb 19, 2026 · Last updated May 18, 2026 · Updated 11 times
Summary
This study looked at whether the drug cadonilimab could help prevent liver cancer from returning in patients who had surgery to remove their tumor but were at high risk of recurrence. The trial planned to enroll 45 adults aged 18-70 with good performance status. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.